← Back to Search

Community Support Network Intervention for Traumatic Brain Injury (SOAR-CSNI Trial)

N/A

Recruiting

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Must not have

Any diagnosed neurological disorder other than brain injury known to affect cerebrovascular, neurocognitive, and/or sensorimotor function (e.g., stroke, Parkinson's, Alzheimer's, cerebral palsy, multiple sclerosis, migraine, seizures, etc.)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up the 1st and 2nd sessions (one month apart) will occur prior to the enrollment to the intervention, the 3rd within 3 days of completing the intervention, and the 4th, 6 months after completing the intervention.

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to improve the quality of life for women experiencing IPV-related TBI by creating evidence-based treatments and informing new policies to help survivors.

Who is the study for?

This trial is for women who have experienced traumatic brain injuries (TBI) due to intimate partner violence (IPV). They should not be pregnant, have other neurological disorders like stroke or Alzheimer's, take medication affecting blood pressure, or have joint-affecting conditions like arthritis.

What is being tested?

The study tests a Community Support Network (CSN) intervention against usual care for women with IPV-related TBI. It aims to integrate TBI knowledge into community support and improve survivors' quality of life.

What are the potential side effects?

Since the interventions involve non-medical community support and standard care practices, there are no direct medical side effects associated with this trial.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a neurological condition affecting my brain function, other than brain injury.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ the 1st and 2nd sessions (one month apart) will occur prior to the enrollment to the intervention, the 3rd within 3 days of completing the intervention, and the 4th, 6 months after completing the intervention.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~the 1st and 2nd sessions (one month apart) will occur prior to the enrollment to the intervention, the 3rd within 3 days of completing the intervention, and the 4th, 6 months after completing the intervention.

This trial's timeline: 3 weeks for screening, Varies for treatment, and the 1st and 2nd sessions (one month apart) will occur prior to the enrollment to the intervention, the 3rd within 3 days of completing the intervention, and the 4th, 6 months after completing the intervention. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Cambridge Brain Science tasks (Now called Creyos) for assessing change in neuroconginitve functions and Task Switching Task for assessing executive functions

Connor-Davidson Resiliency Scale to measure change in resilience

Secondary study objectives

Medical Outcomes study Questionnaire Short Form 36 (SF-36) to measure change in overall health status.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Community Support Network (CSN) intervention groupExperimental Treatment1 Intervention

The SOAR Community Support Network (CSN) intervention includes cognitive training, aerobic exercise, mindfulness meditation, counselling, quality of life tracking.

Group II: Control groupActive Control1 Intervention

Women who have experienced intimate partner violence but no sustained brain injury (Brain Injury Severity Assessment; BISA = 0)

Group III: Usual careActive Control1 Intervention

Participants in this group will receive dose-equivalent usual care

0 / 1Eligibility criteria met